

# Yi-Bin Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6966865/publications.pdf>

Version: 2024-02-01

241  
papers

11,054  
citations

36203

51  
h-index

37111

96  
g-index

243  
all docs

243  
docs citations

243  
times ranked

11749  
citing authors

#	ARTICLE	IF	CITATIONS
1	How I treat with maintenance therapy after allogeneic HSCT. <i>Blood</i> , 2023, 141, 39-48.	0.6	11
2	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	0.6	7
3	Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases. <i>Blood</i> , 2022, 139, 3583-3593.	0.6	10
4	Previously unreported WRAP53 gene variants in a patient with dyskeratosis congenita. <i>Annals of Hematology</i> , 2022, 101, 907-909.	0.8	3
5	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	0.8	75
6	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. <i>Journal of Clinical Oncology</i> , 2022, 40, 189-201.	0.8	79
7	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. <i>Blood Advances</i> , 2022, 6, 2183-2194.	2.5	12
8	JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia. <i>Med</i> , 2022, 3, 42-57.e5.	2.2	11
9	Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e14-e25.	2.2	27
10	A glimpse into what happens after PTCy. <i>Blood</i> , 2022, 139, 479-481.	0.6	0
11	Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure. <i>Leukemia Research Reports</i> , 2022, 17, 100302.	0.2	1
12	Paraneoplastic Pulmonary Alveolar Proteinosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, , .	2.5	0
13	Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. <i>Oncologist</i> , 2022, 27, 685-693.	1.9	23
14	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. <i>Blood</i> , 2022, 139, 2306-2315.	0.6	62
15	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715.	2.5	9
16	Highlights in graft-vs-host disease from the 63rd American Society of Hematology Annual Meeting and Exposition: commentary.. <i>Clinical Advances in Hematology and Oncology</i> , 2022, 20 Suppl 3, 17-23.	0.3	0
17	Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2022, 40, 3985-3993.	0.8	62
18	Declining bone marrow harvest quality over 24 years: a single institution experience. <i>Bone Marrow Transplantation</i> , 2021, 56, 983-985.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.	1.3	15
20	Association Between Baseline Patient-Reported Outcomes and Complications of Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 496.e1-496.e5.	0.6	7
21	Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 479.e1-479.e7.	0.6	10
22	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
23	Acute GVHD: do we trust our gut?. <i>Blood</i> , 2021, 137, 1447-1448.	0.6	0
24	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	2.5	28
25	Acute Myeloid Leukemia Presenting Less Than 3 Weeks After Living Donor Kidney Transplant: A Case Report. <i>Transplantation Proceedings</i> , 2021, 53, 1360-1364.	0.3	1
26	A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 2477-2488.	1.3	8
27	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1878-1887.	0.8	14
28	Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Oncologist</i> , 2021, 26, e2082-e2085.	1.9	2
29	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 885-907.	0.6	12
30	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7.	0.6	10
31	Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2021, 385, 834-843.	13.9	0
32	Distress in a Pandemic - The Association of the Coronavirus Disease-2019 (COVID-19) Pandemic with Distress and Quality of Life in Hematopoietic Stem Cell Transplantation (HSCT). <i>Transplantation and Cellular Therapy</i> , 2021, , .	0.6	8
33	Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia Research</i> , 2021, 109, 106625.	0.4	0
34	Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies. <i>Blood</i> , 2021, 138, 653-653.	0.6	5
35	Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT). <i>Blood</i> , 2021, 138, 409-409.	0.6	10
36	Highlights in graft-vs-host disease from the 2021 Transplantation & Cellular Therapy (TCT) Meetings of the ASTCT and the CIBMTR: commentary.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 14, 19-23.	0.3	0

#	ARTICLE	IF	CITATIONS
37	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. <i>Bone Marrow Transplantation</i> , 2020, 55, 804-810.	1.3	3
38	Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1178-1180.	1.3	2
39	A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 1264-1273.	2.0	15
40	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e122-e133.	2.2	19
41	Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. <i>Bone Marrow Transplantation</i> , 2020, 55, 758-762.	1.3	7
42	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	0.8	216
43	Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. <i>Blood Advances</i> , 2020, 4, 3136-3140.	2.5	28
44	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	0.6	62
45	Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. <i>Blood</i> , 2020, 135, 1739-1749.	0.6	176
46	Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2319-2321.	1.3	5
47	T Cell Clonal Dynamics Determined by High-Resolution TCR- $\hat{I}^2$ Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1567-1574.	2.0	11
48	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	3.3	16
49	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. <i>Blood Advances</i> , 2020, 4, 1656-1669.	2.5	68
50	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 122-126.	2.5	46
51	Current Approaches to Transplantation for FLT3-ITD AML. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 1-8.	1.2	6
52	Biomarker-guided preemption of steroid-refractory graft-versus-host disease with $\hat{I}^{\pm}$ -1-antitrypsin. <i>Blood Advances</i> , 2020, 4, 6098-6105.	2.5	24
53	Pharmacokinetics and Safety of KRN7000 Following Intravenous Infusion of RGI-2001 in Allogeneic Transplant Patients. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
54	Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program. <i>Blood</i> , 2020, 136, 39-40.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	0.6	4
56	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
57	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. <i>Bone Marrow Transplantation</i> , 2019, 54, 497-507.	1.3	11
58	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2383-2387.	2.0	15
59	Coping and Modifiable Psychosocial Factors are Associated with Mood and Quality of Life in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2234-2242.	2.0	28
60	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. <i>Blood</i> , 2019, 134, 860-866.	0.6	178
61	Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 687-705.	0.9	6
62	Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. <i>Cancer</i> , 2019, 125, 3692-3698.	2.0	42
63	Drug-Resistant <i>E. coli</i> Bacteremia Transmitted by Fecal Microbiota Transplant. <i>New England Journal of Medicine</i> , 2019, 381, 2043-2050.	13.9	767
64	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. <i>Blood</i> , 2019, 134, 211-215.	0.6	18
65	Automated detection of neutropenia using noninvasive video microscopy of superficial capillaries. <i>American Journal of Hematology</i> , 2019, 94, E219-E222.	2.0	8
66	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1604-1607.	0.8	29
67	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1202). <i>Lancet Haematology</i> , 2019, 6, e132-e143.	2.2	200
68	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	0.6	129
69	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019, 3, 875-883.	2.5	25
70	Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 4136-4146.	2.5	26
71	Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned. <i>Transplantation</i> , 2019, 103, 2366-2372.	0.5	19
72	Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e17-e22.	2.0	44

#	ARTICLE	IF	CITATIONS
73	Isocitrate dehydrogenase 1 and 2 mutations, 2-oxoglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 541-549.	2.0	23
74	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 720-727.	2.0	47
75	BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML. <i>Blood</i> , 2019, 134, 4602-4602.	0.6	25
76	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	0.6	5
77	Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells. <i>Blood</i> , 2019, 134, 3275-3275.	0.6	1
78	Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Hematology International</i> , 2019, 1, 201-204.	0.7	0
79	Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases. <i>Blood</i> , 2019, 134, 1978-1978.	0.6	0
80	Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4571-4571.	0.6	1
81	Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program. <i>Blood</i> , 2019, 134, 5371-5371.	0.6	0
82	New treatment options for the management of acute graft-versus-host disease. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 482-485.	0.3	0
83	Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1741-1747.	2.0	36
84	Non-invasive detection of severe neutropenia in chemotherapy patients by optical imaging of nailfold microcirculation. <i>Scientific Reports</i> , 2018, 8, 5301.	1.6	19
85	Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2018, 131, 1073-1080.	0.6	26
86	Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. <i>Oncologist</i> , 2018, 23, 624-630.	1.9	21
87	Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. <i>Haematologica</i> , 2018, 103, 522-530.	1.7	28
88	Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation. <i>Cancer</i> , 2018, 124, 2438-2446.	2.0	28
89	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	0.6	140
90	Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach. <i>Human Immunology</i> , 2018, 79, 258-265.	1.2	40

#	ARTICLE	IF	CITATIONS
91	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 514-520.	2.0	31
92	Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. <i>Bone Marrow Transplantation</i> , 2018, 53, 199-206.	1.3	46
93	Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. <i>Blood Advances</i> , 2018, 2, 745-753.	2.5	167
94	Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2285-2292.	2.0	38
95	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2216-2223.	2.0	18
96	Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1836-1840.	2.0	8
97	A Prospective Trial of Extracorporeal Photopheresis for Chronic Graft-versus-Host Disease Reveals Significant Disease Response and No Association with Frequency of Regulatory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2373-2380.	2.0	31
98	Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E331-E333.	2.0	5
99	A Phase 1b Study of Intravenous Vedolizumab Plus Standard of Care for Graft-Versus-Host Disease Prophylaxis in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: 6-Month Results. <i>Blood</i> , 2018, 132, 605-605.	0.6	1
100	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 1650-1650.	0.6	2
101	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 2177-2177.	0.6	2
102	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.	0.6	3
103	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 766-766.	0.6	9
104	Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 601-601.	0.6	13
105	Axicabtagene CiloleuceL in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. <i>Blood</i> , 2018, 132, 92-92.	0.6	74
106	A Phase I/IIb Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2018, 132, 705-705.	0.6	10
107	The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 5784-5784.	0.6	0
108	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 356-356.	0.6	0



#	ARTICLE	IF	CITATIONS
109	Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4587-4587.	0.6	0
110	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. <i>Cancer</i> , 2017, 123, 2035-2042.	2.0	14
111	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	2.0	73
112	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 853-856.	2.0	28
113	Case 11-2017 "A 61-Year-Old Woman with Leg Swelling, Back Pain, and Hydronephrosis. <i>New England Journal of Medicine</i> , 2017, 376, 1461-1471.	13.9	1
114	PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	0.6	214
115	Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2017, 129, 3256-3261.	0.6	34
116	CSF Indirectly Induces Apoptosis of Osteoblasts During Hematopoietic Stem Cell Mobilization. <i>Clinical and Translational Science</i> , 2017, 10, 287-291.	1.5	7
117	High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. <i>Cancer</i> , 2017, 123, 3073-3079.	2.0	41
118	Increased Foxp3 + Helios + Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 625-634.	2.0	59
119	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	1.7	79
120	The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. <i>European Journal of Haematology</i> , 2017, 98, 330-336.	1.1	68
121	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 719-727.	1.7	33
122	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017, 19, 272-284.	0.3	13
123	GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. <i>Bone Marrow Transplantation</i> , 2017, 52, 400-408.	1.3	42
124	Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 783-784.	13.9	170
125	More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2101-2102.	13.9	16
126	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	0.6	210



#	ARTICLE	IF	CITATIONS
127	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigenâ€“Matched Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 126-133.	2.0	10
128	High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 884-888.	0.2	14
129	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	2.3	166
130	Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 699-707.	0.9	4
131	Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2017, 1, 2473-2482.	2.5	16
132	Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease. <i>Blood Advances</i> , 2017, 1, 1919-1922.	2.5	20
133	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Antiâ€“T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Diseaseâ€“Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011.	0.8	258
134	Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance. <i>Advances in Hematology</i> , 2016, 2016, 1-8.	0.6	33
135	The addition of sirolimus to the graftâ€“versusâ€“host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016, 173, 96-104.	1.2	53
136	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	2.0	45
137	Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
138	The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1977-1979.	0.6	2
139	Hydroxyurea for Treatment of Nephrotic Syndrome Associated With Polycythemia Vera. <i>American Journal of Kidney Diseases</i> , 2016, 68, 465-468.	2.1	2
140	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. <i>Lancet Haematology</i> , 2016, 3, e276-e283.	2.2	19
141	Nextâ€“generation sequencingâ€“based detection of circulating tumour <scp>DNA</scp> After allogeneic stem cell transplantation for lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 841-850.	1.2	47
142	Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2134-2140.	2.0	15
143	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.	13.9	488
144	Haematopoietic cell transplantation with and without sorafenib maintenance for patients with <i><scp>FLT</scp>3</i>â€“<scp>ITD</scp> acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2016, 175, 496-504.	1.2	162

#	ARTICLE	IF	CITATIONS
145	Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, e70-e72.	0.8	3
146	Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?. <i>Bone Marrow Transplantation</i> , 2016, 51, 1121-1126.	1.3	11
147	Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 80-85.	2.0	14
148	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 910-918.	2.0	32
149	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 4-10.	2.0	487
150	Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2016, 51, 58-66.	1.3	36
151	A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD). <i>Blood</i> , 2016, 128, 390-390.	0.6	15
152	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 505-505.	0.6	12
153	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 509-509.	0.6	1
154	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	0.6	3
155	Risk Factors and Impact of Neurological Complications after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 5742-5742.	0.6	0
156	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. <i>Blood</i> , 2016, 128, 510-510.	0.6	0
157	Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1583-1588.	2.0	18
158	Case 23-2015: A Woman with Headache, Cognitive Impairment, and Weakness. <i>New England Journal of Medicine</i> , 2015, 373, 1983-1983.	13.9	1
159	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1155-1166.	2.0	104
160	Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1046-1053.	2.0	133
161	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> , 2015, 33, 4167-4175.	0.8	149
162	Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. <i>Cancer</i> , 2015, 121, 226-233.	2.0	61

#	ARTICLE	IF	CITATIONS
163	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. <i>Bone Marrow Transplantation</i> , 2015, 50, 197-203.	1.3	37
164	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2015, 126, 2022-2022.	0.6	1
165	Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit. <i>Blood</i> , 2015, 126, 2104-2104.	0.6	2
166	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2597-2597.	0.6	6
167	The Impact of Pre-Transplant Depression on Outcomes of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 265-265.	0.6	3
168	A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies. <i>Blood</i> , 2015, 126, 389-389.	0.6	1
169	A Multicenter Phase I/II Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 860-860.	0.6	5
170	Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1. <i>Blood</i> , 2015, 126, 864-864.	0.6	7
171	Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone. <i>Blood</i> , 2015, 126, 2126-2126.	0.6	0
172	Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report. <i>Blood</i> , 2015, 126, 3154-3154.	0.6	0
173	Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3310-3310.	0.6	0
174	Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD). <i>Blood</i> , 2015, 126, 1930-1930.	0.6	2
175	miR-145 regulates chemoresistance in hepatocellular carcinoma via epithelial mesenchymal transition. <i>Cellular and Molecular Biology</i> , 2015, 61, 12-6.	0.3	16
176	Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis. <i>Leukemia Research</i> , 2014, 38, 773-780.	0.4	23
177	Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1341-1348.	2.0	52
178	Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2042-2048.	2.0	219
179	Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 186-192.	1.2	14
180	Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. <i>Leukemia</i> , 2014, 28, 658-665.	3.3	121

#	ARTICLE	IF	CITATIONS
181	Outcomes and management strategies for graft failure after umbilical cord blood transplantation. American Journal of Hematology, 2014, 89, 1097-1101.	2.0	16
182	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1729-1736.	2.0	119
183	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
184	Allotransplantation for Patients Age $\geq$ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 960-968.	2.0	37
185	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 951-959.	2.0	37
186	Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 730-734.	2.0	16
187	A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 3964-3964.	0.6	15
188	Comparison of Umbilical Cord Blood to Adult Related and Unrelated Donors. Pancreatic Islet Biology, 2014, , 235-255.	0.1	0
189	Prognostic Understanding, Quality of Life, and Mood in Patients Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 1296-1296.	0.6	3
190	Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations. Blood, 2014, 124, 1045-1045.	0.6	1
191	Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies. Blood, 2014, 124, 3961-3961.	0.6	0
192	Serum Uric Acid Levels during Allogeneic Hematopoietic Cell Transplantation and Subsequent Graft Versus Host Disease. Blood, 2014, 124, 2493-2493.	0.6	0
193	Sequence-Based Discovery of <i>Bradyrhizobium enterica</i> in Cord Colitis Syndrome. New England Journal of Medicine, 2013, 369, 517-528.	13.9	148
194	Trends in all-cause mortality among patients with chronic myeloid leukemia. Cancer, 2013, 119, 2620-2629.	2.0	67
195	Outcomes in Patients Age 70 or Older Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2013, 19, 1374-1380.	2.0	77
196	Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. Journal of Clinical Oncology, 2013, 31, 4199-4206.	0.8	433
197	The evolving landscape in the therapy of acute myeloid leukemia. Protein and Cell, 2013, 4, 735-746.	4.8	23
198	Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. British Journal of Haematology, 2013, 160, 608-617.	1.2	67

#	ARTICLE	IF	CITATIONS
199	Risk Factors for Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1190-1196.	2.0	55
200	Biomarkers for acute GVHD: can we predict the unpredictable?. <i>Bone Marrow Transplantation</i> , 2013, 48, 755-760.	1.3	49
201	Expression of $\alpha 4 \beta 7$ integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD. <i>Bone Marrow Transplantation</i> , 2013, 48, 598-603.	1.3	22
202	Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 981-987.	2.0	43
203	Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 642-646.	2.0	64
204	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. <i>Blood</i> , 2013, 122, 695-695.	0.6	3
205	The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial. <i>Blood</i> , 2013, 122, 704-704.	0.6	3
206	Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance. <i>Blood</i> , 2013, 122, 741-741.	0.6	18
207	Patient Characteristics Associated With Receiving Hematopoietic Stem Cell Transplantation In An Older, Transplant-Appropriate MDS Cohort: The MDS-TAO Study. <i>Blood</i> , 2013, 122, 2929-2929.	0.6	1
208	Do Older Patients With Moderate-Severe Chronic Graft-Versus-Host Disease Differ From Younger Patients?. <i>Blood</i> , 2013, 122, 725-725.	0.6	0
209	Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1130-1136.	0.6	35
210	Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma. <i>Oncologist</i> , 2012, 17, 80-90.	1.9	27
211	Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. <i>Blood</i> , 2012, 119, 4083-4090.	0.6	47
212	Expression of CD30 in patients with acute graft-versus-host disease. <i>Blood</i> , 2012, 120, 691-696.	0.6	47
213	Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 565-574.	2.0	160
214	Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 805-812.	2.0	79
215	Expression of $\alpha 4 \beta 7$ Integrin on Memory CD8+ T-Cells Is Increased in Patients at Presentation of Acute Intestinal Graft-Vs-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S221.	2.0	2
216	Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 76-83.	2.0	76



#	ARTICLE	IF	CITATIONS
217	Case 24-2012. <i>New England Journal of Medicine</i> , 2012, 367, 552-563.	13.9	3
218	The expanding frontier of hematopoietic cell transplantation. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 271-279.	0.7	17
219	Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. <i>Blood</i> , 2012, 119, 1972-1980.	0.6	136
220	MyD88-Dependent TLR1/2 Signals Educate Dendritic Cells with Gut-Specific Imprinting Properties. <i>Journal of Immunology</i> , 2011, 187, 141-150.	0.4	70
221	High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1363-1366.	0.6	10
222	Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2011, 53, e77-e80.	2.9	56
223	Treatment of FLT3-ITD acute myeloid leukemia. <i>American Journal of Blood Research</i> , 2011, 1, 175-89.	0.6	28
224	B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 327-340.	2.1	327
225	Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010, 51, 789-796.	0.6	11
226	Donor-Derived Second Hematologic Malignancies after Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1025-1031.	2.0	47
227	Prophylactic Rituximab After Allogeneic Stem Cell Transplantation Prevents Steroid-Requiring Chronic Graft-Vs.Host Disease. <i>Blood</i> , 2010, 116, 214-214.	0.6	4
228	Reduced Intensity Conditioning (RIC) with Double Umbilical Cord Blood Transplantation Has Similar Outcomes Compared to RIC Transplantation From Related or Unrelated Adult Donors. <i>Blood</i> , 2010, 116, 2367-2367.	0.6	1
229	Risk Factors Associated with the Development of Pneumonitis After High-Dose Chemotherapy with Cyclophosphamide, BCNU, and Etoposide (CBV) Followed by Autologous Stem Cell Transplant. <i>Blood</i> , 2010, 116, 903-903.	0.6	0
230	Up-Regulation of $\alpha 4 \beta 7$ Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1066-1076.	2.0	45
231	Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1447-1454.	2.0	35
232	Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1455-1464.	2.0	52
233	Busulfan Dosing May Affect Survival Following Reduced Intensity Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia.. <i>Blood</i> , 2009, 114, 4328-4328.	0.6	0
234	Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors. <i>Leukemia</i> , 2008, 22, 31-41.	3.3	20

#	ARTICLE	IF	CITATIONS
235	Enzastaurin. Expert Opinion on Investigational Drugs, 2008, 17, 939-944.	1.9	47
236	Bleomycin-Induced Flagellate Erythema. Journal of Clinical Oncology, 2007, 25, 898-900.	0.8	45
237	Primary Effusion Lymphoma. Oncologist, 2007, 12, 569-576.	1.9	236
238	Impact of the Addition of Rituximab to Initial CHOP Chemotherapy Compared with CHOP Alone in Patients with Relapsed Diffuse Large B-Cell Lymphoma Who Underwent Autologous Stem Cell Transplantation.. Blood, 2007, 110, 5124-5124.	0.6	0
239	Acquired Hypocalciuric Hypercalcemia Due to Autoantibodies against the Calcium-Sensing Receptor. New England Journal of Medicine, 2004, 351, 362-369.	13.9	125
240	Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 1627-1632.	3.3	33
241	A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. EJHaem, 0, , .	0.4	0